Could less be more? new study tests lower doses for Crohn's and colitis
NCT ID NCT07303686
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study looks at whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce how often they take the biologic drug ustekinumab. Researchers will monitor blood levels, inflammation, and gut health to see if a lower dose still keeps the disease under control. About 115 participants will either stretch their injections from every 4 weeks to every 8 weeks, or from every 8 weeks to every 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MUHC - Montreal General Hospital
RECRUITINGMontreal, Quebec, H3G1A4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.